1. Revenue declined 6.2% in Q3 compared to the same period last year. For the first 9 months, revenue declined 8.3% compared to the same period last year.
2. Staff cost increased 19.2% in Q3 compared to the same period last year.
3. Profit before income tax decreased 87.3% to $568k in Q3 compared to the same period last year.
4. Cash flow from operations is negative for the quarter at -$1.278m.
5. EPS for the quarter is 0.01c, remaining the same as the last quarter but down from 0.29c in the same quarter last year.
See results here.
We are still in the tunnel but do we see a tiny glow at the end of the tunnel?
A. Although revenue declined 6.2% compared to the same period last year, this is a smaller decline compared to Q2's decline of 12.3%.
B. Staff cost increase of 19.2% is also smaller than Q2's 22.9%.
C. Profit before income tax in Q2 was only $165k. So, Q3's $568k is an improvement.
D. Cash flow from operations in Q2 was a negative $2.3m compared to a smaller negative $1.278m in Q3.
Perhaps, points C and D are the most important indicators that things could be stabilising. However, it is still too early to say for sure.
Having said this, the proposed diversification could throw a spanner in the works. One could only hope that Healthway Medical is not biting off more than it could chew.
On 25 Oct, I suggested that Healthway Medical's share price could have found a floor at 15c. I also mentioned that any rebound would be a good chance for stale bulls to reduce exposure. 17c was never hit as the rebound in price went as high as 16.5c before declining again.
The last session saw Healthway Medical closing at 15.5c. With the MACD, MFI and RSI all in their respective downtrends, a retest of the support at 15c is rather likely. Consolation? Volume has been declining in the last few sessions. So, we could have a soft landing.
Related posts:
Healthway Medical: Second quarter results.
Healthway Medical: Business diversification.
Healthway Medical: A floor at 15c?
No comments:
Post a Comment